Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
QSI
Upturn stock ratingUpturn stock rating

QuantumSi Inc (QSI)

Upturn stock ratingUpturn stock rating
$1.95
Last Close (24-hour delay)
Profit since last BUY18.18%
upturn advisory
Consider higher Upturn Star rating
BUY since 5 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: QSI (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Year Target Price $2.83

Year Target Price $2.83

Analyst’s Price TargetsFor last 52 week
$2.83Target price
Low$0.61
Current$1.95
high$5.77

Analysis of Past Performance

Type Stock
Historic Profit -63.49%
Avg. Invested days 21
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 357.82M USD
Price to earnings Ratio -
1Y Target Price 2.83
Price to earnings Ratio -
1Y Target Price 2.83
Volume (30-day avg) -
Beta 2.91
52 Weeks Range 0.61 - 5.77
Updated Date 06/29/2025
52 Weeks Range 0.61 - 5.77
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.68

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -2982.42%

Management Effectiveness

Return on Assets (TTM) -25.22%
Return on Equity (TTM) -40.23%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 137274326
Price to Sales(TTM) 103.93
Enterprise Value 137274326
Price to Sales(TTM) 103.93
Enterprise Value to Revenue 39.87
Enterprise Value to EBITDA 0.63
Shares Outstanding 163560992
Shares Floating 146748948
Shares Outstanding 163560992
Shares Floating 146748948
Percent Insiders 13.94
Percent Institutions 31.75

Analyst Ratings

Rating 4
Target Price 2.83
Buy 1
Strong Buy 1
Buy 1
Strong Buy 1
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

QuantumSi Inc

stock logo

Company Overview

overview logo History and Background

QuantumSi Inc. was founded in 2013. It is focused on developing next-generation protein sequencing technology. It went public via a SPAC merger in 2021. Milestones include developing and launching its Platinum protein sequencing platform.

business area logo Core Business Areas

  • Protein Sequencing Technology: Develops and commercializes a protein sequencing platform (Platinum) based on next-generation semiconductor chip technology.

leadership logo Leadership and Structure

Dr. Jonathan Rothberg is the founder and Chairman of the Board. More specific details on the leadership team and organizational structure are available in company SEC filings and the company website.

Top Products and Market Share

overview logo Key Offerings

  • Platinum: QuantumSi's Platinum is a protein sequencing platform that leverages semiconductor chip technology. Competitors include traditional protein analysis methods and other emerging protein sequencing technologies. Specific market share data is not readily available, as this is a nascent market. The number of users and revenue are not disclosable.

Market Dynamics

industry overview logo Industry Overview

The protein sequencing market is an emerging field with significant growth potential, driven by increasing demand for proteomics research and personalized medicine.

Positioning

QuantumSi aims to be a leader in protein sequencing by offering a high-throughput, cost-effective platform. Its competitive advantage lies in its use of semiconductor technology.

Total Addressable Market (TAM)

The TAM for protein sequencing is estimated to be in the billions of dollars. QuantumSi is positioned to capture a portion of this market by offering a novel technology platform.

Upturn SWOT Analysis

Strengths

  • Novel Semiconductor-Based Protein Sequencing Technology
  • High-Throughput Capabilities
  • Potential for Cost-Effectiveness
  • Experienced Leadership Team

Weaknesses

  • Relatively New Company
  • Limited Commercial Track Record
  • Dependence on Single Product (Platinum)
  • Unprofitable

Opportunities

  • Growing Protein Sequencing Market
  • Partnerships with Pharmaceutical and Research Institutions
  • Expansion into New Applications (e.g., diagnostics)
  • Further Technological Advancements

Threats

  • Competition from Established Protein Analysis Methods
  • Emergence of Other Novel Protein Sequencing Technologies
  • Regulatory Hurdles
  • Economic Downturn

Competitors and Market Share

competitor logo Key Competitors

  • ILMN
  • PACB
  • AVNW
  • QDEL

Competitive Landscape

QuantumSi's advantage lies in its semiconductor-based technology, but it faces competition from established players with broader product portfolios and market presence.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been limited due to the early stage of commercialization.

Future Projections: Future growth projections depend on the adoption of the Platinum platform and are subject to analyst estimates, which can be found on financial analysis websites.

Recent Initiatives: Recent initiatives include product launches, partnerships, and expansion of manufacturing capacity.

Summary

QuantumSi is an early-stage company developing innovative protein sequencing technology. Its semiconductor-based platform has the potential to disrupt the market, but it faces challenges related to commercialization and competition. The company's financial health relies on successful adoption of its Platinum platform and partnerships. Investors should monitor its progress in penetrating the market and managing its cash flow.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • QuantumSi Inc. SEC Filings
  • QuantumSi Inc. Investor Relations
  • Financial News Outlets
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company-specific factors can change rapidly, and investors should conduct their own due diligence before making any investment decisions. Market share data is approximate and may vary based on different sources and methodologies.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About QuantumSi Inc

Exchange NASDAQ
Headquaters Branford, CT, United States
IPO Launch date 2021-06-10
President, CEO & Director Mr. Jeffrey Alan Hawkins
Sector Healthcare
Industry Medical Devices
Full time employees 149
Full time employees 149

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company offers Platinum NGPS instrument that provides single molecule amino acid level resolution with a streamlined workflow, including automated data analysis that accessible to researchers in all laboratory types; Platinum Pro NGPS instrument, a single molecule amino acid resolution, which provides an enhanced user interface, cloud or on instrument data analysis and an available pro mode; Library preparation kits to prepare protein sample for sequencing; Barcoding Kits to optimize the workflow and performance of technology; and Sequencing Kits contains the reagents and consumables used to perform NGPS on the Platinum or Platinum Pro instrument. It also provides Platinum Analysis Software, a cloud-based solution that automates data analysis workflows and provides a user-friendly interface and visualization of the sequencing results. Its products are used in antibody characterization, biomarker identification, protein identification, protein variants, protein barcoding, and post translational modification analysis applications. Quantum-Si incorporated was founded in 2013 is headquartered in Branford, Connecticut.